CSIMarket Company Name, Ticker, Industry, else..


Novavax inc   (NASDAQ: NVAX)
Other Ticker:  
 

Novavax inc

NVAX's Fundamental analysis



Looking into Novavax Inc growth rates, revenue grew by 610.3 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 986

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 11.44 %

Novavax Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on NVAX's Growth


Novavax Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Novavax Inc PEG ratio is at -0.01 Novavax Inc realized cash reduction of $ -1.22 per share in trailing twelve-month period.
Company
2.44
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.95.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.


• More on NVAX's Valuation
 
 Total Debt (Millions $) 170
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 3,391,789
 Net Income/Employee (TTM) $ 1,293,776
 Receivable Turnover (TTM) 17.94
 Tangible Book Value (Per Share $) -1.06

Novavax Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Novavax Inc PEG ratio is at -0.01 Novavax Inc realized cash outflow of $ -1.22per share in trailing twelve-month period.
Company
2.44
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.95.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.


• More on NVAX's Valuation

•  Market Capitalization (Millions $) 1,195
•  Shares Outstanding (Millions) 178
•  Employees 370
•  Revenues (TTM) (Millions $) 1,255
•  Net Income (TTM) (Millions $) 479
•  Cash Flow (TTM) (Millions $) -217
•  Capital Exp. (TTM) (Millions $) -9
•  Total Debt (Millions $) 170
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 3,391,789
•  Net Income/Employee(TTM) $ 1,293,776
•  Receivable Turnover Ratio (TTM) 17.94
•  Tangible Book Value (Per Share $) -1.06

•  Market Capitalization (Millions $) 1,195
•  Shares Outstanding (Millions) 178
•  Employees 370
•  Revenues (TTM) (Millions $) 1,255
•  Net Income (TTM) (Millions $) 479
•  Cash Flow (TTM) (Millions $) -217
•  Capital Exp. (TTM) (Millions $) -9


    NVAX's Profitability Comparisons
Novavax Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 77.33 %.

Novavax Inc net profit margin of 77.8 % is currently ranking no. 5 in Biotechnology & Pharmaceuticals industry, ranking no. 9 in Healthcare sector and number 51 in S&P 500.


Profitability by Segment
Total 77.8 %



  Ratio
•   Capital Ratio (MRQ) 2.06
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.88
•  Inventory Turnover Ratio (TTM) 17.13



Novavax Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 77.33 %.

Novavax Inc net profit margin of 77.8 % is currently ranking no. 5 in Biotechnology & Pharmaceuticals industry, ranking no. 9 in Healthcare sector and number 51 in S&P 500.

• More on NVAX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com